Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Ugur AkcaDepartment of Biomedical Engineering, University of Alabama, Birmingham, Alabama.
Yujun ZhangDepartment of Radiology, University of Alabama, Birmingham, Alabama; and.
Norio YasuiDepartment of Radiology, University of Alabama, Birmingham, Alabama; and.
Christopher HensleyDepartment of Radiology, University of Alabama, Birmingham, Alabama; and.
Anna SoraceDepartment of Radiology, University of Alabama, Birmingham, Alabama; and.
Benjamin M LarimerDepartment of Radiology, University of Alabama, Birmingham, Alabama; and.
Jonathan McConathyDepartment of Radiology, University of Alabama, Birmingham, Alabama; and jmcconathy@uabmc.edu.
Funding
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for gliomaR01CA279143 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAMES M MARKERT, Anna C Sorace · 2023 to 2026
$2.3M
Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer ImmunotherapyDP2CA261453 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LARIMER, BENJAMIN M · 2020 to 2020
$2.2M
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancerR01CA276540 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C, YANKEELOV, THOMAS E · 2023 to 2025
Immune checkpoint inhibitor (ICI) therapy is effective and in routine clinical use for various cancers, but accurately identifying which patients will respond remains a significant challenge. The PET agent
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model. · full record | OpenQuestion